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Abstract
A large fraction of the patients with rheumatoid arthritis (RA) develop specific autoantibod-
ies, which until recently were only of two types, rheumatoid factor (RF) and anti-citrullinated
protein antibodies (ACPA). We aimed to replicate important findings about a recently
described third type of specific autoantibodies, anti-carbamylated protein (anti-CarP) anti-
bodies, because they have been described based only in the homemade ELISA from a sin-
gle laboratory. Our study included 520 patients with established RA and 278 healthy
controls of Spanish ancestry and it was done with an independently performed ELISA. The
prevalence and pattern of environmental, clinical and genetic associations of the anti-CarP
antibodies were similar to the previously described. Notably, the presence and titers of anti-
CarP correlated with the presence and titers of ACPA, but the anti-CarP antibodies did not
share the known genetic and exposure risk factors of the ACPA. In addition, anti-CarP anti-
bodies were independently associated with a higher (10.5%) prevalence of bone erosions.
The reproducibility of these characteristics across laboratories and European subpopula-
tions, indicates the wide validity of the results and suggests that determination of anti-CarP
antibodies could contribute to explain RA pathogenesis and identify clinically relevant
patient subgroups.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation in
multiple peripheral joints with a symmetric distribution, which untreated will lead to bone ero-
sions, deformities, significant handicap and life shortening [1]. RA shows a notable inter-indi-
vidual variability that poses many problems for treatment and for prediction of evolution [2,3].
RA etiology is complex with an environmental component and a polygenic susceptibility com-
ponent together with other factors like the larger prevalence in women than in men. The
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identification of autoantibodies specific of RA has been critical in advancing the understanding
of the disease and in the classification of patients with a more uniform clinical pattern. The two
well-known autoantibodies are rheumatoid factor (RF), against the Fc of the immunoglobulins,
and the anti-citrullinated protein antibodies (ACPA) that are assayed with the anti-cyclic
citrullinated peptide (CCP) test. Recently, a third type of specific autoantibodies has been
described, which show reactivity against carbamylated proteins (anti-CarP) [4]. They could be
useful for prediction, diagnosis or follow-up of the patients [4–9].
A possible limitation of this perspective of progress is that the natural autoantigens recog-
nized by anti-CarP antibodies are unknown, and the assays have been performed with in vitro
carbamylated proteins from either fetal calf serum or fibrinogen [4]. Differences in preparation
of the antigen could lead to conflicting results as has already been observed. In effect, no cross
reactivity between anti-CarP or anti-carbamylated fibrinogen antibodies and ACPA has been
reported with ELISA performed by the group behind most research in these antibodies, based
in the Rheumatology Laboratory of the Leiden University Medical Center [4]. In contrast,
extensive cross-reactivity between carbamylated fibrinogen and citrullinated fibrinogen has
been reported by other group [10]. Therefore, it is unclear if the characteristics described with
the Leiden ELISA for the anti-CarP antibodies are reproducible in different settings. These
characteristics show that the anti-CarP antibodies are independent of the risk factors associated
with ACPA positive RA [4,9]. Whereas ACPA positive RA is associated with the shared epitope
(SE) alleles in the HLA-DRB1 locus, the R620W risk allele of PTPN22 and with smoking [11–
13], no association has been observed for the anti-CarP antibodies with any of these genetic or
environmental risk factors [9]. On the contrary, the anti-CarP antibodies were associated with
the HLA-DRB103 allele, which is not a risk factor for ACPA positive RA [9]. However, studies
by the same research group have shown that the anti-CarP antibodies seem to have a patho-
genic role in the RA disease process. The pieces of evidence pointing in this direction include
association with radiological damage of RA, which is independent of the ACPA status [4,7];
detection of anti-CarP antibodies in blood samples taken before the onset of clinical symptoms
of RA [5–8]; and experiments in mice showing that immunization with cabamylated peptides
was able to elicit erosive arthritis [14].
These results are exciting because they identify a new RA autoantibody type with pathogenic
relevance that does not share the known etiological factors with the other autoantibodies.
Research in these antibodies will complement our understanding of RA and could be of clinical
utility. However, we need independent replication of the findings in different laboratories to be
confident on these results. In addition, replication of the characteristics attributed to anti-CarP
antibodies in populations with different prevalence of RA risk factors is required to assess their
generality.
Here, we present our determination of anti-CarP antibodies in Caucasian Spanish RA
patients using antigen and assays prepared in our laboratory. The results confirm the indepen-
dence of these antibodies from the risk factors that are known for ACPA positive RA and their
independent association with RA bone erosions, which are the widely reported characteristics
of these antibodies.
Material and Methods
Patient and control samples
Sera from 520 RA patients fulfilling 1987 ACR classification criteria [15], and from 278 healthy
donors were included in the study. Clinical characteristics of patients (Table 1) have been
described elsewhere [16,17]. All patients and controls were Spanish Caucasians, and they have
provided their written informed consent. Collection of samples was approved by the Cómite
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Etico de Investigación Clinica de Galicia. Available information included HLA-DRB1 geno-
types determined by sequencing, PTPN22 rs2476601 genotypes, anti-CCP2 and IgM RF titers,
smoking status (coded as never or ever smoker) and bone erosions as already described
[16,17]. SE alleles of HLA-DRB1 were considered to include the 22 alleles coding for the
QKRAA, QRRAA and RRRAA 70–74 amino acids of HLA-DRB1 [18]. A single rheumatolo-
gist assessed the most recent hands and feet radiographs of the patients to distinguish between
presence/absence of definite bone erosions. Time since disease onset to the set of radiographs
was long and very variable (median of 18.0 years (7.9–30.4 IQR) in 20 patients taken at ran-
dom). This radiographic evaluation was done with total independence of this study.
Carbamylation and Anti-CarP antibodies detection
In vitro carbamylation and ELISA detection of antibodies were done following the described
protocol with minor changes [4]. It involved incubation of FCS (F-7524, Sigma-Aldrich,
St. Louis, Missouri) at 4 mg/ml with 1M of KCNO, or with 1M KCl as control, during 15 h at
37°C. After incubation, the samples were dialysed against H2O with 0.25 NaCl at 4°C during
24h and used as antigen for ELISA. An aliquot was used to assess the efficiency of carbamyla-
tion by chromatographic analysis of the hydrolysed amino acids. Acid hydrolysis was done
with HCl 6N during 18h at 110°C. A Biochrom 30 amino acid analyzer (Biochrom, UK) with
an ionic exchange column and lithium citrate buffers of different pH were used for separation.
Quantification involved post-column reaction with ninhydrin using L-Norleucine as internal
standard. The change of lysine to homocitrulline was determined as the fraction of the total
amount of amino acids. The anti-Carp FCS antibodies were assayed with ELISA. Separate
Nunc MaxiSorp flat-bottom 96 well plates were coated with carbamylated and native FCS over-
night at 10 μg/mL in 50 μL of carbonate-bicarbonate buffer 0.1M pH 9.6. The plates were
washed with PBS-0.05% Tween and blocked for 6 hours at 4°C with 100 μl of PBS-1% BSA.
Diluted serum (50 μL at 1:50 in PBS-1% BSA-0.05%Tween) was incubated on ice overnight.
IgG antibodies were detected using ALP-conjugated goat anti-human IgG (Jackson Immunore-
search Europe, UK) and SIGMAFAST p-Nitrophenyl phosphate as substrate following manu-
facturers' recommendations. Reactivity to native FCS was subtracted from the reactivity to
carbamylated FCS and relative quantification was done against serial dilutions of a pool of pos-
itive patient sera. The cut-off for positivity was set as the 98th percentile of the healthy controls.
Statistical analysis
Concordance between positivity of the different antibodies was analyzed with the Goodman
and Kruskal's gamma coefficient (γ). Interpretation of his coefficient in a 2x2 contingency table
Table 1. Characteristics of the patients with RA included in the study.
Feature n (%)
Gender (women) 399 (76.7)
Age of disease onset, median (IQR) years 48.6 (35.8–57.2)
Duration of follow-up, median (IQR) years 12.1 (5.3–20.7)
Ever smokers 97 (20.3)
Erosions 325 (65.7)
anti-CCP positive 334 (64.2)
RF positive 301 (60.2)
Shared epitope, carrier 299 (57.5)
PTPN22, carrier 137 (26.5)
doi:10.1371/journal.pone.0161141.t001
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goes from -1.0 = all results are discordant, to +1.0 = all results are concordant. Relationship
between antibodies titers was analyzed with Spearman rank correlation (rs). Multivariate logis-
tic regression analysis was used to evaluate the effect of each antibody type conditional on the
other antibodies. These analyses were used to explore association with HLA-DRB1, PTPN22,
smoking and erosions. Gender, age of diagnosis and time of follow-up were included as covari-
ates without interaction terms. In addition, stratified analyses with contingency tables were
done. P values lower that 0.05 were considered statistically significant. All analyses were done
with Statistica 7.0 (StatSoft, Tulsa, OK), the eulerAP software was used to draw area propor-
tional Venn diagrams [19].
Results
Patients showed established RA with clinical characteristics (Table 1) that have already been
described [17]. The frequency of RA risk factors in these patients is very different from the
reported in Northern Europeans, as already shown [16,17]. Specifically, carriers of SE (53.9%)
and smokers (20.3%) were less frequent among our RA patients than in the Dutch
(SE = 64.3%, P = 2.3 x10-4; smoking = 52.1%, P = 9.7 x10-29) and Swedish (SE = 73.6%, P = 3.9
x10-18; smoking = 64.9%, P = 1.5 x10-67) patients included in previous analysis of the character-
istics of the anti-CarP antibodies [4,9].
The procedure of in vitro carbamylation induced a notable change in the relative abun-
dances of lysine and homocitrulline among the FCS proteins, with a marked decrease in lysine
(from 7.8% to 0.2%) and increase in homocitrulline (from 0.7% to 5.1%) (S1 Fig). ELISA using
carbamylated FCS led to the identification of 29.4% of the RA patients showing this specificity
(Fig 1), which is markedly less than the fraction of anti-CCP positive patients. Accordingly,
there was a similar fraction of patients that showed anti-CCP antibodies and lacked anti-CarP
antibodies (39.6%), and the status of anti-CarP positivity was moderately concordant with the
anti-CCP status (γ = 0.60, 95% CI: 0.47–0.75). A similar degree of concordance was observed
with the RF status (γ = 0.56, 95% CI: 0.41–0.72). This level of concordance was clearly lower
than the present between anti-CCP and RF (γ = 0.82, 95% CI: 0.75–0.89). In addition, the titers
of anti-CarP antibodies (ranging from 120 to over 1511 AU) were correlated with the anti-
CCP titers (range from 6 to 6522 units; rs = 0.27, P = 5.3 x 10
−10). A subset of patients of special
interest included the 4.8% patients that were anti-CarP+ and anti-CCP-. These results are simi-
lar to the already reported in other studies [4,7,9], where anti-CarP+ patients were 35.6 to 45%
and the anti-CarP+/anti-CCP- were 4 to 8% of the patients. Given that about half of these
patients were RF positive (Fig 1), the fraction of seronegative RA patients was only slightly
reduced by the consideration of the anti-CarP+ patients from 26.2% to 23.9%.
A previous study showed a weak association of HLA-DRB103 with anti-CarP antibodies in
anti-CCP-/anti-CarP+ patients (as well as, in anti-CCP-/anti-CarP- patients) compared with
healthy controls [9]. We did not observe association with the 03 alleles in this or any other
subgroup of patients, but there was a nominal deviation in the same direction previously
reported (OR = 1.5, P = 0.2 in all the subjects and OR = 1.6, P = 0.2 in the non-carriers of SE
alleles).
Radiological damage has been associated with anti-CarP antibodies, either as damage at par-
ticular time points or as radiological progression [4,7]. The information available from our
patients did not allow us studying the same time points or progression; only the presence of
bone erosions at the most recent radiographic exam. Presence of erosions was associated with
the anti-CarP status (OR = 2.4, P = 2.0 x 10−4). A conditional analysis on the presence of anti-
CCP antibodies showed also significant association of the anti-CarP status with erosions
(OR = 1.76, P = 0.026) indicating the independent contribution of the anti-CarP status. This
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Fig 1. Distribution of patients with RA positive for the different autoantibodies.We observed that anti-CarP antibodies were not
associated with the SE alleles (Fig 2A). This lack of association was found in all analyses performed, which included either all the SE
alleles together (OR = 1.1, P = 0.6), or only theHLA-DRB1*01 alleles (OR = 0.9, P = 0.7), or the *04 alleles (OR = 1.0, P = 0.9), or the
*1001 allele (OR = 1.2, P = 0.7). In addition, we did not observe association in analyses conditional on the anti-CCP status (OR = 0.8,
P = 0.4), the RF status (OR = 0.9, P = 0.6) or both (OR = 0.8, P = 0.3). In a similar way, there was no association of the anti-CarP status
with the PTPN22R620W polymorphism (Fig 2B). Again, this result was consistent in the direct analysis (OR = 0.9, P = 0.7), and in the
conditional on other autoantibodies (OR = 0.8, P = 0.5 conditional on anti-CCP; OR = 1.0, P = 0.8 conditional on RF; and OR = 0.9, P = 0.7
conditional in the two other autoantibodies). Finally, we did not observe association of the anti-CarP antibodies with smoking (OR = 1.0,
P = 0.9; Fig 2C). We should note that the anti-CCP positive status was associated with the SE alleles (P = 2.4 x 10−7), showed a stronger
association than the anti-CCP negative status with the PTPN22R620W polymorphism (P = 0.002 for anti-CCP positive and P = 0.13 for
anti-CCP negative patients), but it was not associated with smoking (P = 0.65) in our patients, as we already have noted previously [16,17].
All these analyses were adjusted for gender, age at disease onset and time of follow-up.
doi:10.1371/journal.pone.0161141.g001
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relationship was also observed with stratified analysis (Fig 3), where the strata including anti-
CarP+ patients showed numerically more erosions (a mean of 10.5%) than the anti-CarP-
patients.
Discussion
We have replicated the following characteristics of anti-CarP antibodies: they were specific of
RA, but less sensitive than the anti-CCP antibodies and less correlated with them than RF; in
addition, the anti-CarP antibodies were not associated with the RA risk factors, the HLA-DRB1
and PTPN22 risk alleles or with smoking; on the contrary, they were associated with the pres-
ence of erosions with independence of the ACPA status. These characteristics have previously
Fig 3. Prevalence of RA bone erosions in anti-CCP and anti-CarP defined subgroups. Error bars represent 95% CI. P value from
logistic regression analysis adjusted for gender, age of diagnosis and time of follow-up.
doi:10.1371/journal.pone.0161141.g003
Fig 3. Prevalence of RA bone erosions in anti-CCP and anti-CarP defined subgroups. Error bars
represent 95% CI. P value from logistic regression analysis adjusted for gender, age of diagnosis and time of
follow-up.
doi:10.1371/journal.pone.0161141.g003
Reproducible Anti-CarP Antibodies in Rheumatoid Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0161141 August 18, 2016 7 / 10
been described in studies done with an ELISA we have replicated in a different laboratory and
in European subpopulations with notably different prevalence of RA risk factors [4,7,9]. Our
results provide in this way wide validity to the anti-CarP antibody characteristics that define
them as a second system of autoantibodies targeting post-transcriptional modifications of
endogenous proteins in the pathogenesis of RA.
The characteristics of anti-CarP antibodies replicated here provide new opportunities for
the understanding of RA pathogenesis and for classification of patients. They could facilitate
the discovery of new risk factors specific of the subset of patients producing the anti-CarP anti-
bodies. In this regard, the antecedent of ACPA is very illustrative, as their discovery has led to
the identification of the best-known pathogenic pathway in RA [1,20–22]. This pathway
includes smoking and periodontal disease as sources of citrullination of proteins, specific
HLA-DRB1 alleles to present citrullinated peptides, and other genetic factors as positive modu-
lators of antibody mediated autoreactivity; epitope spreading together with maturation of the
antibody response as steps preceding clinical onset of RA, and the effect of ACPA in stimulat-
ing osteoclasts for the RA bone erosions. For anti-CarP, it would be necessary to identify spe-
cific risk factors, to analyze if they share with ACPA mechanisms to escape immunological
tolerance as targeting neoantigens, as well as, epitope spreading and maturation. It would be
also necessary, to clarify the mechanisms leading to the increased risk of radiological damage
associated with the anti-CarP antibodies. Are they triggering osteoclast differentiation and acti-
vation as the anti-citrullinated vimentin antibodies [23]? Are they cooperating with other anti-
bodies to erosions, as indicated for ACPA and RF [24]?
In addition, our results seem to anticipate that anti-CarP antibodies could have significant
clinical utility. The presence of these antibodies in a fraction of ACPA negative patients and
their association with radiographic progression, as well as their presence preceding the onset of
arthritis, have been signaled as indication of their possible utility [4–8]. The two first features
were assessed and replicated in our patients. The utility of these changes for individual patients
is still unclear and would need to be specifically addressed. Other possible area of utility, not
yet addressed, is as biomarkers of response to treatment.
In conclusion, we think it is already possible to consider the anti-CarP antibodies as inde-
pendent RA autoantibodies that do not share the same risk factors with ACPA, but that are
associated with radiological damage. Demonstration of the wide reproducibility of these char-
acteristics makes of them a firm ground on which to base further studies to clarify the anti-
CarP role in the clinic and in RA pathogenesis.
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